224 related articles for article (PubMed ID: 30303528)
1. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing.
Schmider J; Kumar K; LaForest C; Swankoski B; Naim K; Caubel PM
Clin Pharmacol Ther; 2019 Apr; 105(4):954-961. PubMed ID: 30303528
[TBL] [Abstract][Full Text] [Related]
2. Automation Opportunities in Pharmacovigilance: An Industry Survey.
Ghosh R; Kempf D; Pufko A; Barrios Martinez LF; Davis CM; Sethi S
Pharmaceut Med; 2020 Feb; 34(1):7-18. PubMed ID: 32036574
[TBL] [Abstract][Full Text] [Related]
3. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
[TBL] [Abstract][Full Text] [Related]
4. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
[TBL] [Abstract][Full Text] [Related]
5. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.
Salas M; Petracek J; Yalamanchili P; Aimer O; Kasthuril D; Dhingra S; Junaid T; Bostic T
Pharmaceut Med; 2022 Oct; 36(5):295-306. PubMed ID: 35904529
[TBL] [Abstract][Full Text] [Related]
6. Utility of social media and crowd-intelligence data for pharmacovigilance: a scoping review.
Tricco AC; Zarin W; Lillie E; Jeblee S; Warren R; Khan PA; Robson R; Pham B; Hirst G; Straus SE
BMC Med Inform Decis Mak; 2018 Jun; 18(1):38. PubMed ID: 29898743
[TBL] [Abstract][Full Text] [Related]
7. Intelligent Telehealth in Pharmacovigilance: A Future Perspective.
Edrees H; Song W; Syrowatka A; Simona A; Amato MG; Bates DW
Drug Saf; 2022 May; 45(5):449-458. PubMed ID: 35579810
[TBL] [Abstract][Full Text] [Related]
8. Is pharmacovigilance of biologicals cost-effective?
Claus B
Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
[TBL] [Abstract][Full Text] [Related]
9. Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions.
Hauben M
Clin Ther; 2023 Feb; 45(2):117-133. PubMed ID: 36732152
[TBL] [Abstract][Full Text] [Related]
10. Portable automatic text classification for adverse drug reaction detection via multi-corpus training.
Sarker A; Gonzalez G
J Biomed Inform; 2015 Feb; 53():196-207. PubMed ID: 25451103
[TBL] [Abstract][Full Text] [Related]
11. Grouping the pharmacovigilance terms with a hybrid approach.
Dupuch M; Dupuch L; Perinet A; Hamon T; Grabar N
Stud Health Technol Inform; 2012; 180():235-9. PubMed ID: 22874187
[TBL] [Abstract][Full Text] [Related]
12. Drug safety in Africa: a review of systems and resources for pharmacovigilance.
Ndagije HB; Walusimbi D; Atuhaire J; Ampaire S
Expert Opin Drug Saf; 2023; 22(10):891-895. PubMed ID: 37676033
[TBL] [Abstract][Full Text] [Related]
13. Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability.
Pinheiro LC; Kurz X
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1308-1310. PubMed ID: 35959980
[No Abstract] [Full Text] [Related]
14. Artificial Intelligence in Pharmacovigilance and COVID-19.
Bhardwaj K; Alam R; Pandeya A; Sharma PK
Curr Drug Saf; 2023; 18(1):5-14. PubMed ID: 35382726
[TBL] [Abstract][Full Text] [Related]
15. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
[TBL] [Abstract][Full Text] [Related]
16. Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file.
Furlan G
Drug Saf; 2012 Aug; 35(8):615-22. PubMed ID: 22788233
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance.
Roux E; Thiessard F; Fourrier A; Bégaud B; Tubert-Bitter P
IEEE Trans Inf Technol Biomed; 2005 Dec; 9(4):518-27. PubMed ID: 16379369
[TBL] [Abstract][Full Text] [Related]
18. Why Are We Still Creating Individual Case Safety Reports?
Streefland MB
Clin Ther; 2018 Dec; 40(12):1973-1980. PubMed ID: 30420290
[TBL] [Abstract][Full Text] [Related]
19. Artificial intelligence in pharmacovigilance: Do we need explainability?
Hauben M
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1311-1316. PubMed ID: 35747938
[No Abstract] [Full Text] [Related]
20. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?
Ball R; Dal Pan G
Drug Saf; 2022 May; 45(5):429-438. PubMed ID: 35579808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
